Skip to content
NovaVIPZone

Individuals Coming Off Weight-Loss Medications Put On Weight Four Times Faster Than People Using Diet and Exercise

Illustration of medical syringe and scale
Weight management involves long-term strategies.

Fresh analysis indicates that patients who come off popular slimming jabs like Wegovy and Mounjaro may regain lost weight far faster than those who stop conventional diet and exercise regimens.

Research printed in a leading health publication demonstrates that while overweight individuals frequently drop substantial amounts of their total mass while using the jabs, the weight comes back at an average rate of nearly a kilo each month upon discontinuation.

"Individuals purchasing these treatments should be aware of the danger of rapid rebound weight gain when the medication concludes," cautioned lead investigator Dr. Susan Jebb.

Such speed of regain implies a return to pre-treatment mass in about one and a half years.

Weighing Treatments

The research, which reviewed 37 of studies involving over 9,000 of participants, contrasted the effects of these new drugs with older methods.

Researchers point out that individuals who lose weight through dieting typically have a more gradual creep back—around 100 grams monthly—once they finish.

Understanding the Quick Rebound

Doctors believe the mode of action of the drugs is key to understanding the heightened weight return.

GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which controls hunger.

"Sustained high doses of GLP-1 concentrations several times higher than normal may cause the system to produce less of its own natural hormone, and could lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition researcher.

"Discontinuation of this GLP-1 'fix' means appetite is no longer kept in check, making binge eating a significant risk."

A Chronic Disease?

The NHS recommend the injections for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.

Professionals say that, given the high risk of relapse, the treatment should be considered ongoing.

This perspective is echoed by pharmaceutical companies, who state that the findings "highlight the persistent character of obesity," comparing it to managing diseases like diabetes.

Patient Accounts

Individuals who have stopped the jabs explain a intense resurgence of hunger.

"It felt as if a trigger activating and I was suddenly ravenous," recalled one woman.

The struggle is exacerbated if individuals have not established lasting dietary or behavioural modifications during therapy.

Significant Interest

Survey data suggest that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with demand continuing to grow.

  • Use is more common among women compared to males.
  • The 40s and 50s age group shows the greatest usage rates.
  • A large proportion obtain the drugs through private healthcare rather than public health services.

Finally, researchers caution that while GLP-1 drugs are potent agents for weight loss, they are not a standalone solution and maintained weight loss hinges on integrated behavioural support.

By

Jennifer Watkins

Elara Vance is a digital content strategist and community manager with over a decade of experience in creating engaging online experiences.

NovaVIPZone

Type to search articles.